Hepatera
Web21 ott 2014 · Hepatera develops novel drugs for the treatment of liver diseases for the Russian market. The company's first product, Myrcludex B, is aimed at the treatment of chronic hepatitis B and delta. Web1 nov 2024 · Hepatera LLC , Moscow, Russia Business: Infectious Date completed: 3/20/12 Type: Venture financing Raised: Not disclosed Investors: Maxwell Biotech Venture Fund; …
Hepatera
Did you know?
Web2 set 2016 · Hepatera Ltd. ClinicalTrials.gov Identifier: NCT02888106 Other Study ID Numbers: MYR 203 : First Posted: September 2, 2016 Key Record Dates: Results First Posted: February 25, 2024: Last Update Posted: April 30, 2024 Last Verified: March 2024 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Web21 ott 2014 · Hepatera Ltd is a private Russian biotech company funded by Maxwell Biotech Venture Fund. Hepatera develops novel drugs for the treatment of liver …
WebHEPA: [adjective] being, using, or containing a filter usually designed to remove 99.97 percent of airborne particles measuring 0.3 micrometers or greater in diameter passing … WebIn 2007 graduated from I.M. Sechenov First Moscow State Medical University. Is engaged in research activities and medical analytics for more than 8 years. Has extensive experience in project management in the fields of commercial medicine, medical insurance, trade marketing and human resources. In 2014 joined «Maxwell Biotech Group» team and ...
WebHepatera is a Russian biotechnology company founded in 2011. The main activity of the company is the search for and evaluation of promising drug candidates, as well as … Web25 mag 2024 · Hepatera is Maxwell Biotech Venture Fund's Portfolio Company. The main activity of the company is the development of safe and effective drugs for the treatment …
An entry inhibitor that is being developed by MYR GmbH for the treatment of chronic HDV and HBV infections. Received its first approval on 31 July 2024 in the EU. Approved for use in chronic HDV infection in HDV RNA positive adult patients with compensated liver disease.
WebEntry inhibitor Myrcludex B Hepatera/MYR GmbH Phase 2 cccDNA inhibitor Preclinical RNA silencers AROHBV Arrowhead Phase 1/2a ARB-1467 Arbutus Phase 2 ARB-1740 Arbutus Preclinical ALN-HBV Alnylam Phase 1/2 GSK 3228836 GlaxoSmithKline/Ionis Phase 1 Core protein/capsid inhibitors AL-3778 Alios/Johnson & Johnson Phase 1/2 ABI-H0731 … firefly mountain hot springs ncWeb22 dic 2015 · PEG-INF-a is used for the treatment of chronic hepatitis delta. The study endpoints are virological response (HBsAg, hepatitis delta virus ribonucleic acid (HDV … firefly mouthwash orangeWebHEPA (/ ˈ h ɛ p ə /, high-efficiency particulate air) filter, also known as high-efficiency particulate absorbing filter and high-efficiency particulate arrestance filter, is an efficiency … ethan baxley panama cityWeb6 mar 2014 · A group of 48 patients infected with the hepatitis B virus (HBV) have been enrolled in the phase IIa clinical trial of Myrcludex B by Russian biotech company Hepatera Ltd. Hepatera is financed by ... firefly mouthwash for boysWeb1 nov 2024 · Hepatera November 01, 2024. US FDA approval tracker: October 2024. April 14, 2024. EASL 2024 – Research reminds hep B bulls that progress will be slow. … firefly mount saint michaelWeb25 mag 2024 · MOSCOW, May 25, 2024 /PRNewswire/ --. MYR GmbH and its development partner Hepatera LLC today announced that the European Medicines Agency (EMA) granted "PRIME eligibility" for Myrcudex B, a first in class entry inhibitor for Hepatitis Delta (D) virus. "It is very encouraging that the European regulator recognizes the importance … ethan baxterWebHeptathela is a genus of spiders that includes the Kimura spider ( Heptathela kimurai ). They are trapdoor spiders of the family Liphistiidae and are found in Japan, including Okinawa … firefly mouthwash for kids